[HTML][HTML] Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series

AHME Ketabforoush, R Chegini, S Barati… - Biomedicine & …, 2023 - Elsevier
Abstract Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with high
mortality and morbidity rate affecting both upper and lower motor neurons (MN). Muscle …

Therapeutic landscape for Batten disease: current treatments and future prospects

TB Johnson, JT Cain, KA White… - Nature Reviews …, 2019 - nature.com
Batten disease (also known as neuronal ceroid lipofuscinoses) constitutes a family of
devastating lysosomal storage disorders that collectively represent the most common …

T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression

S Yazdani, C Seitz, C Cui, A Lovik, L Pan… - Nature …, 2022 - nature.com
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, involving
neuroinflammation and T cell infiltration in the central nervous system. However, the …

Complement: Bridging the innate and adaptive immune systems in sterile inflammation

MW Lo, TM Woodruff - Journal of Leucocyte Biology, 2020 - academic.oup.com
The complement system is a collection of soluble and membrane-bound proteins that
together act as a powerful amplifier of the innate and adaptive immune systems. Although its …

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial

W Camu, M Mickunas, JL Veyrune, C Payan… - …, 2020 - thelancet.com
Abstract Background Low-dose interleukin-2 (ld-IL-2) enhances regulatory T-cell (Treg)
function in auto-inflammatory conditions. Neuroinflammation being a pathogenic feature of …

Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation

G Oliveros, CH Wallace, O Chaudry, Q Liu, Y Qiu, L Xie… - Brain, 2023 - academic.oup.com
Alzheimer's disease is a multifactorial disease that exhibits cognitive deficits, neuronal loss,
amyloid plaques, neurofibrillary tangles and neuroinflammation in the brain. Hence, a multi …

Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact

F De Marchi, I Munitic, A Amedei, JD Berry… - Neuroscience & …, 2021 - Elsevier
Amyotrophic lateral sclerosis (ALS) is a debilitating and rapidly fatal neurodegenerative
disease. Despite decades of research and many new insights into disease biology over the …

[HTML][HTML] Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis

GY Wang, SL Rayner, R Chung, BY Shi, XJ Liang - Materials Today Bio, 2020 - Elsevier
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a
progressive neurodegenerative disease that affects both upper and lower motor neurons …

The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis

Y Zhang, A Burberry, JY Wang, J Sandoe… - Genes & …, 2018 - genesdev.cshlp.org
While a mutation in C9ORF72 is the most common genetic contributor to amyotrophic lateral
sclerosis (ALS), much remains to be learned concerning the function of the protein normally …

Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients

C Milligan, N Atassi, S Babu, RJ Barohn… - Muscle & …, 2021 - Wiley Online Library
Abstract Introduction/Aims We tested safety, tolerability, and target engagement of
tocilizumab in amyotrophic lateral sclerosis (ALS) patients. Methods Twenty‐two …